XML 27 R17.htm IDEA: XBRL DOCUMENT

Note 11 - Subsequent Events	3 Months Ended
Note 11 - Subsequent Events	Mar. 31, 2016
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 11 - SUBSEQUENT EVENTS The Private Offering On April 15, 2016 we completed the final closing of the Private Offering, at which we issued an additional 420,260 shares of Series B Preferred Stock to accredited investors, for total gross proceeds of $525,325. On April 15, 2016 the Board determined at the Compensation Committee meeting of the Board of Directors that each board member will be compensated an option grant of 40,000 options per year, plus 5,000 options for serving as the Chair of a committee. Options shall have 10-year expiration dates, 24-month vesting cycles, and a strike price of $1.25 per share, or more in future time periods to match the fair market value of the company’s Common stock. On June 17, 2016, Atrinsic, Inc. held a Special Meeting of Stockholders (the “Special Meeting”). At the Special Meeting, the Company’s stockholders approved a third amendment and restatement to the Company’s Amended and Restated Certificate of Incorporation, effective June 17, 2016. On March 25, 2016, the Company’s Board of Directors approved the filing of a Certificate of Ownership and Merger with the Secretary of State of the State of Delaware in order to change the Company’s name to Protagenic Therapeutics, Inc. The Name Change was effected at the Effective Time through a short-form merger pursuant to Section 253 of the Delaware General Corporation Law (the “DGCL”), by merging the Company’s wholly owned Protagenic Therapeutics, Inc. subsidiary with and into the Company, with the Company as the surviving corporation in the merger. The DGCL did not require stockholder approval of the Name Change.